Olaparib in HR-deficient, metastatic triple-negative breast and platinum-sensitive relapsed ovarian cancers without germline mutations in BRCA1/2: phase 2 EMBRACE trial.

Authors

Katrin M Sjoquist, Alexander Dobrovic, Kristy P Robledo, Ksenija Nesic, Sally Baron-Hay, Sumitra Ananda, Nicole McCarthy, Jeffrey Goh, Christopher Steer, Nick Murray, Sonia Yip, Linda R Mileshkin, J Lynn Fink, Garry Chang, Lisa Bailey, Yvonne Lee, Danka S Zebic, U G Imalki U Kariyawasam, Kristy Shield-Artin, Andrew Jarratt, Justin Bedő, Anthony T Papenfuss, Olga Kondrashova, Matthew J Wakefield, Cassandra J Vandenberg, Martin R Stockler, Clare L Scott, Paul M Waring

Published in

British journal of cancer. Jul 08, 2026. Epub Jul 08, 2026.

Abstract

Homologous recombination (HR) deficiency (HRD) from germline BRCA1/2 mutations (gBRCAm) sensitizes high-grade serous ovarian cancer (HGSOC) and triple-negative breast cancer (TNBC) to PARP inhibitors (PARPi), as may promoter methylation of BRCA1 (meBRCA1) or RAD51C (meRAD51C) or mutation of non-BRCA HR genes. This trial evaluated olaparib in platinum-sensitive, relapsed HGSOC (PSROC) and metastatic TNBC (mTNBC) with non-gBRCA HRD.
Single-arm phase 2 trial of olaparib 300 mg orally twice daily. Tumour meBRCA1/meRAD51C determined by methylation-sensitive, high-resolution melting PCR and targeted sequencing. Unmethylated cases underwent HR gene mutation testing.
objective tumour response rate (OTRR) at 6 months(m).
progression-free survival (PFS), OTRR according to HR gene aberration, and safety.
Total 22 enrolled: promoter methylation detected in 8/15 HGSOC and 5/7 TNBC, and pathogenic variants (PV) in non-BRCA HR genes. OTRR at 6 m was 40% HGSOC and 0% TNBC. OTRR was 38% in methylated cases vs 43% for other HRD. 6 m/12 m PFS were 53% / 25% (HGSOC), and 17% / 0% (TNBC).
Olaparib demonstrated activity in HGSOC beyond gBRCAm, including with meBRCA1 or gRAD51C PV. Olaparib had limited activity in pre-treated TNBC. Effects of prior chemotherapy on meBRCA1/meRAD51C require exploration to improve patient selection for PARPi.
Australian New Zealand Clinical Trials Registry Registration number ACTRN 12617000855325.

PMID:
42420629
Bibliographic data and abstract were imported from PubMed on 09 Jul 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.